Our study shows that complement components (C3, ASP, C4, C5, and CFB) are almost all related to the risk and severity of NAFLD, indicating that the above complement factors are expected to be potential biomarkers for clinical diagnosis and treatment of NAFLD, which is worthy of further study in the future. This evidence concerns the gene C5 and metabolic dysfunction-associated steatotic liver disease.